Armitage Roseanne, Cole Darwynn, Suppes Trisha, Ozcan Mehmet E
Department of Psychiatry, Sleep Study Unit, The University of Texas Southwestern Medical Center, 2201 Inwood Road, Dallas, TX 75235, USA.
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1065-70. doi: 10.1016/j.pnpbp.2004.05.048.
Sleep disturbances are strongly associated with mood disorders, although the majority of data have been obtained in patients with major depressive disorder. Studies reporting results in bipolar disorder are few, and results have not been consistent. Clozapine is a prototype of atypical antipsychotics, which is effective in improving symptoms of manic episodes in patients with bipolar disorder, or schizoaffective disorder, bipolar type and has been shown to influence sleep in other psychiatric disorders. The present study evaluated the sleep effects of clozapine in bipolar and schizoaffective disorders.
Participants were 11 women and 4 men (range:28-53 years of age, mean 40.9+/-8.6 years), all with a history of mania by DSM-IV criteria for either bipolar I disorder or schizoaffective disorder, bipolar type. They participated in a sleep study at baseline and again after 6 months initiation of clozapine add-on therapy.
Sleep latency was longer on clozapine and the number of awakenings were increased, whereas time in bed (TIB) and total sleep period (TSP) were increased (range: F=6.2-17.9; df=l,12; p<0.05). Although none of the individual sleep stage showed significant treatment changes, both Stage 2 and slow-wave sleep were increased and Stage 2 decreased on clozapine. Subjective sleep measures improved on clozapine with a small but significant improvement in how rested patients felt upon awakening (t=-2.1; df=26; p<0.05).
Clozapine prolonged sleep latency, improved restedness, and increased total sleep time. Although lack of a control group limits interpretation of these results, they are in general agreement with studies in other psychiatric populations, and support the view that clozapine is primarily a NREM sleep enhancer. The improvement in restedness may be of positive clinical consequence.
睡眠障碍与情绪障碍密切相关,尽管大多数数据是在重度抑郁症患者中获得的。报道双相情感障碍结果的研究较少,且结果并不一致。氯氮平是非典型抗精神病药物的原型,对改善双相情感障碍或双相型分裂情感性障碍患者的躁狂发作症状有效,并且已被证明会影响其他精神疾病中的睡眠。本研究评估了氯氮平对双相情感障碍和分裂情感性障碍患者睡眠的影响。
参与者为11名女性和4名男性(年龄范围:28 - 53岁,平均40.9±8.6岁),均符合DSM - IV标准中双相I型障碍或双相型分裂情感性障碍的躁狂病史。他们在基线时参加了一项睡眠研究,并在开始氯氮平附加治疗6个月后再次参加。
服用氯氮平时睡眠潜伏期延长,觉醒次数增加,而卧床时间(TIB)和总睡眠时间(TSP)增加(范围:F = 6.2 - 17.9;自由度 = 1,12;p < 0.05)。尽管各个睡眠阶段均未显示出显著的治疗变化,但服用氯氮平时2期睡眠和慢波睡眠均增加,2期睡眠减少。服用氯氮平后主观睡眠指标有所改善,患者醒来时的休息感觉有小幅但显著的改善(t = -2.1;自由度 = 26;p < 0.05)。
氯氮平延长睡眠潜伏期,改善休息状态,并增加总睡眠时间。尽管缺乏对照组限制了对这些结果的解释,但它们总体上与其他精神疾病人群的研究一致,并支持氯氮平主要是一种非快速眼动睡眠增强剂的观点。休息状态的改善可能具有积极的临床意义。